Gene delivery is, arguably, the biggest bottleneck in gene therapy. Adeno-associated viruses (AAVs) are the historical mainstay, but they are expensive to manufacture and have payload limits and ...
An early-stage company is using machine learning to design bespoke nonviral delivery methods for future gene therapies. Nanite, set up two years ago, plans to use machine learning to design polymers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results